Poland· PL-100491783
Supliven
A elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente product containing produkt złożony, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente is registered in 11 of 19 countries.
Countries holding a registration under ATC B05XA31 (elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente · ATC B05XA31
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Produkt złożony
- Manufacturer
- Delfarma Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- B05XA31
- ATC class
- Elektrolyte, Kombinationen mit anderen Arzneistoffen, inkl. reine Spurenelemente
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991528683
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
102 interactions on record for elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente · interactions on record
102 records
- 4 severe
- 12 moderate
- 86 minor
Most severe, free to view
- RaltegravirJ05AJ01severe
- ElvitegravirJ05AJ02severe
- RaltegravirJ05AX08severe
- ElvitegravirJ05AX11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B05XA31
Elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b4a35e60-eda9-4495-8d5b-210afc7957e6 GET /v1/drugs/b4a35e60-eda9-4495-8d5b-210afc7957e6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": null,
"packaging": "05909991528683 ¦ Rp ¦ 152692\n20 ampułek 10 ml",
"substance": null,
"common_name": "Produkt złożony",
"pl_product_id": "100491783",
"pozwolenie_nr": "299/23",
"auth_procedure": "IR",
"authorisation_validity": "2028-12-21"
}See everything about elektrolyte, kombinationen mit anderen arzneistoffen, inkl. reine spurenelemente.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.